Evidence map›Paper›PMID 37465947›Full record

ArticleCirculation. Heart failure2023

Inhibition of Pyk2 Improves Cx43 Intercalated Disc Localization, Infarct Size, and Cardiac Function in Rats With Heart Failure.

Li Zheng, Gaelle Spagnol, Devashri R Gandhi, Kanika Sharma, Vikas Kumar, Kaushik P Patel, Paul L Sorgen

Open access · bronzeAbstract read
In one paragraph

Article in Circulation. Heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Cx45 regulation by kinases and impact of expression in heart failure.Journal of molecular and cellular cardiology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Li ZhengDepartment of Biochemistry and Molecular Biology (L.Z., G.S., P.L.S.), University of Nebraska Medical Center, Omaha.
Gaelle SpagnolDepartment of Biochemistry and Molecular Biology (L.Z., G.S., P.L.S.), University of Nebraska Medical Center, Omaha.
Devashri R GandhiDepartment of Genetics, Cell Biology, and Anatomy (D.R.G., K.S., V.K.), University of Nebraska Medical Center, Omaha.
Kanika SharmaDepartment of Genetics, Cell Biology, and Anatomy (D.R.G., K.S., V.K.), University of Nebraska Medical Center, Omaha.
Vikas KumarDepartment of Genetics, Cell Biology, and Anatomy (D.R.G., K.S., V.K.), University of Nebraska Medical Center, Omaha.
Kaushik P PatelDepartment of Cellular and Integrative Physiology (K.P.P.), University of Nebraska Medical Center, Omaha.ORCID 0000-0002-4500-0819
Paul L SorgenDepartment of Biochemistry and Molecular Biology (L.Z., G.S., P.L.S.), University of Nebraska Medical Center, Omaha.ORCID 0000-0002-7766-2083
University of Nebraska Medical Center · US

Funding

Mechanisms of Gap Junction RegulationR01GM072631 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SORGEN, PAUL L · 2006 to 2025
$6.4M
Nebraska Center for Nanomedicine- Pilot ProjectsP30GM127200 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BRONICH, TATIANA K · 2018 to 2022
$5.7M
Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
Novel Target Mechanism (Renal Denervation) to Reduce Sodium Retention in Chronic Heart FailureR01DK114663 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PATEL, KAUSHIK P, ZHENG, HONG · 2017 to 2021
$2.1M
Novel target mechanism (renal nerves) for the beneficial actions of SGLT2 inhibition in congestive heart failureR01DK129311 · NIDDK · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PATEL, KAUSHIK P, ZHENG, HONG · 2021 to 2024
$2.0M
LSM 710 Zeiss Confocal MicroscopeS10RR027301 · NCRR · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHRISTMAN, JUDITH K · 2010 to 2010
$461k
NCRR NIH HHS S10 RR027301NIDDK NIH HHS R01 DK114663NIDDK NIH HHS R01 DK129311NIGMS NIH HHS P30 GM106397NIGMS NIH HHS P30 GM127200NIGMS NIH HHS R01 GM072631
6 · The paper itself

Abstract

backgroundHeart failure causes changes in Cx43 (Connexin43) regulation that are associated with arrhythmic heart disease. Pyk2 (proline-rich tyrosine kinase 2) is activated in cardiomyopathies and phosphorylates Cx43 to decrease intercellular communication. This study was designed to determine if Pyk2 inhibition improves cardiac function in a myocardial infarction (MI)-induced heart failure model in rats.

methodsMI (ligation of left anterior descending artery) rats were treated with the Pyk2 inhibitor PF4618433. Hemodynamic and structural parameters were monitored in Sham (n=5), MI-vehicle (n=5), and MI-PF4618433 (n=8) groups. Heart tissues were collected after 6 weeks to assess Pyk2 and Cx43 protein level and localization.

resultsPF4618433 produced no observed adverse effects and inhibited ventricular Pyk2. PF4618433 reduced the MI infarct size from 34% to 17% (

conclusionsUnlike other attempts to decrease Cx43 remodeling after MI-induced heart failure, inhibition of Pyk2 activity maintained Cx43 at the intercalated disc. This may have aided in the reduced infarct size (acute time frame) and improved cardiac function (chronic time frame). Additionally, we provide evidence that Pyk2 is activated following MI in human left ventricle, implicating a novel potential target for therapy in patients with heart failure.

Indexed as

Heart FailureMyocardial InfarctionAnimalsConnexin 43Focal Adhesion Kinase 2HumansMyocardiumRatsVentricular RemodelingConnexin 43Focal Adhesion Kinase 2Gja1 protein, ratcardiac functiongap junctionheart failurephosphorylationtarget

Identifiers

PMID37465947
PMCPMC10524803
OpenAlexW4384663667

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.